Rasio rega marang prakiraan pendapatan Immutep Limited (IMMP)

Immutep Limited business depends on global logistics and the stability of supplies from Asia. The company relies on developments in Europe and Australia to create LAG-3 protein-based immunotherapy. Active R&D processes are currently focused on releasing data regarding the treatment of lung and breast cancer. The current value is 2.70, and the GURU.Markets system displays this chart of the projected P/S dynamics.

IMMP Immutep Ltd: Multiplikator forward rega marang pendapatan ing interval 04.07.2022 - 13.11.2026

Rincian analitis perusahaan Immutep Corp (IMMP)

- rega saiki lan proyeksi nilai saham:

Rega saham Immutep|IMMP - Target median analis

- rincian kapitalisasi pasar:

Nilai pasar Immutep Corp|IMMP - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- indikator nilai buku ekuitas:

Aset Bersih saben Siji Saham Immutep|IMMP - Aset Bersih Perusahaan|Rasio Kapitalisasi marang Aset Bersih immutep.com|IMMP - Total Aset Perusahaan

- data tingkat utang lan likuiditas finansial:

- data bathi bisnis lan rasio investasi:

IMMP - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Immutep Limited|IMMP - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Immutep Limited ADR|IMMP - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Immutep Corp|IMMP - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Immutep|IMMP - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan immutep.com|IMMP - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Immutep Limited

- data dodolan lan asil:

IMMP - Volume dodolan perusahaan|Prakiraan volume dodolan Immutep|IMMP - Koefisien rega marang pendapatan|Rasio rega marang prakiraan pendapatan Immutep Corp

Analisis wiwitan perusahaan:IMMP (Immutep)

For Immutep Limited (IMMP), a developer of advanced LAG-3 immunotherapy for oncology, the firm's forward P/S ratio serves as an indicator of market expectations regarding the future commercialization of its developments. This ratio correlates current market capitalization with projected revenue, reflecting the dynamics of risk reassessment and business growth potential, which necessitates caution during sharp spikes on the chart to avoid correction losses.

Pesaing langsung

Multiplikator Forward P/S MRUS (Merus)|Rasio kapitalisasi marang dodolan sing dikarepake Anixa Biosciences (ANIX)|ATOS - Rasio rega marang prakiraan pendapatan|Context Therapeutics (CNTX) - Multiplikator forward rega marang pendapatan|mersana.com (MRSN) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan briacell.com|Multiplikator forward rega marang pendapatan EPIX|Multiplikator Forward P/S QT Imaging Holdings